Mifamurtide-TFA-MTP-PE-TFA-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEMifamurtideTFACat.No.:HY-13682CSynonyms:MTP-PETFA;L-MTP-PETFA;CGP19835TFA分⼦式:C₆₁H₁₁₀F₃N₆O₂₁P分⼦量:1351.52作⽤靶点:Others作⽤通路:Others储存⽅式:4°C,sealedstorage,awayfrommoisture*Insolvent:-80°C,6months;-20°C,1month(sealed

storage,awayfrommoisture)溶解性数据体外实验DMSO:25mg/mL(18.50mM;ultrasonicandwarmingandheatto60°C)MassSolvent1mg5mg10mgConcentration制备储备液1mM0.7399mL3.6995mL7.3991mL5mM0.1480mL0.7399mL1.4798mL10mM0.0740mL0.3700mL0.7399mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存⽅式和期限：-80°C,6months;-20°C,1month(sealedstorage,awayfrommoisture)。-80°C储存时，请在6个⽉内使⽤，-20°C储存时，请在1个⽉内使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶)1.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(1.85mM);Clearsolution2.请依序添加每种溶剂：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:2.5mg/mL(1.85mM);Suspendedsolution;Needultrasonic1/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE3.请依序添加每种溶剂：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(1.85mM);ClearsolutionBIOLOGICALACTIVITY⽣物活性MifamurtideTFA(MTP-PETFA)穆拉⼆肽(MDP)的类似物，⼀种⾮特异性免疫调节剂，通过刺激激活巨噬细胞和单核细胞的免疫应答⽽发挥作⽤。MifamurtideTFA⼀种孤⼉药，NOD2的特异性配体，⽤作胰岛素增敏剂。MifamurtideTFA具有⽤于⾻⾁瘤研究的潜⼒。体外研究MifamurtideTFA(MTP-PETFA;100µM)inducesareductionofMG63cellsnumberwhenco-culturedwithmacrophages[3].MifamurtideTFA(100µM)increasesboththeM1polarizationmarkeriNOSandtheM2polarizationmarkerCD206mRNAs;bothpro-inflammatory(IL-1β,IL-6)andanti-inflammatory(IL-4,IL-10)cytokines.MifamurtideTFAincreasestheirontransporterDMT1protein[3].L-mifamurtideTFA(5,5000nM;for48hours)alonehasnodirecteffectontheproliferationrateofthetwoosteosarcomacelllinesMOS-JandKHOSinvitroorinvivo[1].MifamurtideTFAactsasanonspecificimmunomodulatorbyactivatingmacrophagesandmonocytesrelatedtotheupregulationoftumoricidalactivityandsecretionofpro-inflammatorycytokinesincludingtumornecrosisfactor(TNF)-a,interleukin(IL)-1,IL-6,IL-8,IL-12,nitricoxide(NO),prostaglandinE2(PGE2)andPGD2[3].体内研究MifamurtideTFA(MTP-PETFA;1mg/kg;i.v.;twiceperweekfor4weeks)causesatrendofdiminishedspontaneouslungmetastasisdissemination[1].MifamurtideTFA(50μg/mouse)improvesglucosetoleranceduringendotoxemiainmice.MifamurtideTFA(equivalentto20μgMDP;4timesperweekfor5weeks)improvesglucosetoleranceinHFD-fedmicewithoutalteringbodymass[2].AnimalModel:C57BL/6,BALB/cmicewithKHOSosteosarcomacells[1]Dosage:1mg/kgAdministration:IV;twiceperweekfor4weeksResult:Causedatrendofdiminishedspontaneouslungmetastasisdisseminationinxenogeneic(KHOS)andsyngeneic(MOS-J)models.REFERENCES[1].KevinBiteau,etal.L-MTP-PEandzoledronicacidcombinationinosteosarcoma:preclinicalevidenceofpositivetherapeuticcombinationforclinicaltransfer.AmJCancerRes.2016Feb15;6(3):677-89.[2].JosephFCavallari,etal.MuramylDipeptide-BasedPostbioticsMitigateObesity-InducedInsulinResistanceviaIRF4.CellMetab.2017May2;25(5):1063-1074.e3.[3].FrancescaPunzo,etal.MifamurtideandTAM-likemacrophages:effectonproliferation,migrationanddifferentiationofosteosarcoma2/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemEcells.Oncotarget.2020Feb18;11(7):687-698.McePdfHeightCaution:Product